CLSA President & CEO Sara Radcliffe reacts to the President’s proposed $6 billion cut to the NIH’s budget in this San Diego Union-Tribune article.
CLSA’s Brett Johnson, Sr. Director of Policy & Regulatory Affairs, provides analysis and cites concerns regarding Assembly Bill 265, legislations introduced in the California state legislature that would ban drug companies from offering consumers coupons for drugs that have a lower cost alternative.
CLSA’s 2017 California Life Sciences Industry report featured in Bloomberg BNA regarding VC funding levels for the life sciences sector.
CLSA featured in a MassDevice article regarding the reintroduction of legislation to repeal the 2.3% medical device tax.
CLSA Pres. & CEO Sara Radcliffe was featured in GEN News, applauding the Congressional passage of the 21st Century Cures Act.
Did you miss the 2016 CLSA Pantheon Awards? Check out this article from the San Francisco Business Times.
CLSA’s 2017 California Life Sciences Industry Report featured in the San Diego Union-Tribune.
Via BioSpace, for a newly mortar-boarded PhD in the life sciences or a seasoned veteran of the pharma and biotech world, when searching for a new job, it’s a pretty basic notion to look for work where the jobs are.
Via The San Diego Union-Tribune: In a sign of growing interest in Los Angeles County as a major biomedical hub, the California Life Sciences Association has opened an office in Monrovia.
A new study conducted by the Orange County Business Council (OCBC) found that CLSA member Allergan’s California operations generated a combined annual economic activity in the state of approximately $6.35 billionand net economic impact of $3.45 billion. The economic impact is a direct result of the Company’s strong influence on employment in the state, generating more than 16,600 direct, indirect and induced jobs, with annual total statewide labor income of ~$1.55 billion.